AstraZeneca
agreed to invest in U.S. biotech enterprise
CinCor Pharma
in a offer perhaps valued at $1.8 billion, the British pharmaceutical big mentioned Monday.
The supply price of $26 a share represents a 121% premium to CinCor’s (ticker: CINC) closing cost on Friday, and will see
AstraZeneca
(AZN.U.K.) pay out $1.3 billion up entrance.
